Terms: = Sarcomas AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Prognosis
4 results:
1. DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting keap1-Mediated NRF2 Ubiquitination.
Wang X; Zhou T; Yang X; Cao X; Jin G; Zhang P; Guo J; Rong K; Li B; Hu Y; Liu K; Ma P; Qin A; Zhao J
Adv Sci (Weinh); 2023 May; 10(14):e2204438. PubMed ID: 36965071
[TBL] [Abstract] [Full Text] [Related]
2. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.
Liu W; Zhao Y; Wang G; Feng S; Ge X; Ye W; Wang Z; Zhu Y; Cai W; Bai J; Zhou X
Redox Biol; 2022 Jul; 53():102344. PubMed ID: 35636015
[TBL] [Abstract] [Full Text] [Related]
3. Expression of the Nrf2 and keap1 proteins and their clinical significance in osteosarcoma.
Zhang J; Wang X; Wu W; Dang H; Wang B
Biochem Biophys Res Commun; 2016 Apr; 473(1):42-46. PubMed ID: 26987716
[TBL] [Abstract] [Full Text] [Related]
4. Clinical characteristics and prognosis of primary leiomyosarcoma of the pancreas: a systematic review.
Xu J; Zhang T; Wang T; You L; Zhao Y
World J Surg Oncol; 2013 Nov; 11():290. PubMed ID: 24219646
[TBL] [Abstract] [Full Text] [Related]
